Navigation Links
Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula
Date:9/11/2009

CHERRY HILL, N.J., Sept. 11 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), announced today that Legacy Biotechnologies, Inc., its joint venture partner, has informed the company that Reme-Flu(TM) has been secured as the trade name for its homeopathic remedy for helping to prevent and treat flu-like symptoms resulting from influenza, including swine flu. The Reme-Flu(TM) formula consists of a two-part protocol. Part one contains clinically researched ingredients that have been shown to lessen both the duration and severity of flu symptoms. Part two consists of homeopathic sublingual tinctures that are focused on helping lessen respiratory symptoms commonly associated with the flu. This uniquely designed product's two-part protocol flu remedy provides a comprehensive and effective means for safely treating symptoms of the flu.

Homeopathy has a long and successful track record for helping to safely prevent and treat flu symptoms, including typical aches and pains that accompany the flu. During the last flu pandemic, occurring in 1918, homeopathy's performance was outstanding. According to a May, 1921 article in the Journal of the American Institute of Homeopathy, Dr. T A McCann stated that of 26,000 cases of the Spanish Flu treated allopathically (conventional treatment), the mortality rate was 28.2%. Conversely, of the 26,000 cases of Spanish Flu treated with homeopathy, the mortality rate was 1.05%. At the same time, statistics collected from Connecticut of over 6,600 cases of Spanish Flu treated homeopathically showed a mortality rate of less than 1%. During the same pandemic, the Homeopathic Medical Society reported the same impressive statistical findings for 1,500 cases treated with homeopathic remedies in the Washington D.C. area.

About Legacy Biotechnologies, Inc.

Legacy Biotechnologies, Inc. is an independent, privately owned firm specializing in research and development of nutraceutical and cosmeceutical formulations. They specialize in creating innovative and cutting-edge compounds that address all facets of health. Its president, Steve Kushner, has been working in this field for over 26 years and has created several original formulas that have been marketed both on a national basis and abroad. Mr. Kushner's experience allows Legacy Biotechnologies, Inc. to excel at all phases of the health and nutrition industry. In addition to research and development, Legacy Biotechnologies, Inc. is also well versed in the manufacturing process, procurement of raw materials, creation of promotional material, and marketing of products.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy(TM), a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen(TM), which promotes a healthy glucose metabolism; Cinnechol(TM), designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink (R), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink (R). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Company Contact:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex, Inc. Finalizes Joint Venture Agreement for the Development of Broad Spectrum All-Natural Flu Remedies
2. The KonLin Letter Issues Featured Stock Update on Nuvilex, Inc. in Its September 2009 Edition
3. Nuvilex, Inc. Sets Times and Locations for Upcoming Shareholder Meetings
4. Nuvilex, Inc. Announces Business Update Conference Call
5. Nuvilex, Inc. Announces Monthly Investor Conference Call
6. Nuvilex, Inc. Announces Investor Conference Call and Open House
7. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
8. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
9. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
10. eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company
11. JAG Media Holdings, Inc. Announces Agreement with The Investor Relations Group, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dianne Michael Insurance Agency, an ... County, is embarking on a charity drive with the aim of generating support ... orphaned or neglected senior dogs in the Cincinnati region, and LuvFurMutts volunteers also ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... consulting services to residential and commercial clients in the northern Alabama and Georgia ... Nobis Works. , Since 1977, Nobis Works has built a network of support ...
(Date:12/7/2016)... ... ... Kenall Manufacturing, a leader in sealed healthcare lighting for more than 30 ... sealed, LED luminaire that meets the needs of everyone in the patient room by ... , A 2’ x 4’ model features four modes: reading, ambient, standard and high ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e lançamento ... do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Stretta procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, by ... , , ...
(Date:12/8/2016)... 2016  A new study by a pair of ... opioid therapy to treat chronic pain is not only ... harmful consequences, including death. Palliative care physicians ... Mehta , M.D., authored the study which provides a ... The study was published in the December 2016 edition ...
(Date:12/8/2016)... , Dec. 8, 2016 A Small Business ... National Institutes of Health (NIH) to Phoenix ... The grant will seek to determine ... device, which utilizes electromagnetic waves to treat Alzheimer,s Disease. ... novel technology to possibly treat other neurologic disorders such ...
Breaking Medicine Technology: